Story perspectives

FDA Approves Rasonque for Metastatic Pancreatic Cancer

8/26/2026

Summary

Story summary

The FDA approved the pill Rasonque (daraxonrasib) for adults with metastatic pancreatic cancer on Aug 26 2026.
Approval used the National Priority Voucher program, cutting review time to one-two months and arriving six months early.
A study of 500 patients showed median survival of 13.2 months versus 6.7 months with standard chemotherapy.
Common side effects included rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, reduced appetite, and bleeding.

1 of 1

Story summary

The FDA approved the pill Rasonque (daraxonrasib) for adults with metastatic pancreatic cancer on Aug 26 2026.
Approval used the National Priority Voucher program, cutting review time to one-two months and arriving six months early.
A study of 500 patients showed median survival of 13.2 months versus 6.7 months with standard chemotherapy.
Common side effects included rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, reduced appetite, and bleeding.